SCHEMBL984635

SCHEMBL984635

c1ccc(CN2CCC(Cc3ccccc3)(c3ccc4cc[nH]c4c3)C2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.62
SLC6A2 P23975 5/20 0.62
SLC6A4 P31645 5/20 0.62
SLC6A3 Q01959 5/20 0.62
KCNH2 Q12809 2/20 0.52
MAPK14 Q16539 3/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NR3C1 P04150 1/20 0.45
FAAH O00519 1/20 0.41
TSHR P16473 2/20 0.40
OPRL1 P41146 1/20 0.40
CYP3A4 P08684 1/20 0.40
CCR3 P51677 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984260 0.92 SLC6A2 (0.63) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL983580 0.86 SLC6A2 (0.60) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL981123 0.82 KMT2A (0.45) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL984198 0.81 CYP2D6 (0.64) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL982050 0.81 SLC6A2 (0.64) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL984138 0.81 SLC6A2 (0.66) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL980402 0.80 SLC6A2 (0.63) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
Indole SCHEMBL2794626 0.78 CYP2D6 (0.43) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL980929 0.78 CYP2D6 (0.64) CYP2D6SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL982082 0.78 SLC6A2 (0.63) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 CYP2D6 97/4885SLC6A2 6/4885SLC6A4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.